Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Down 36.3% in May

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a significant decline in short interest in May. As of May 31st, there was short interest totalling 5,800 shares, a decline of 36.3% from the May 15th total of 9,100 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 23,500 shares, the days-to-cover ratio is currently 0.2 days.

Barinthus Biotherapeutics Trading Down 4.2 %

BRNS traded down $0.08 on Friday, hitting $1.83. 7,672 shares of the company were exchanged, compared to its average volume of 17,342. The firm has a 50-day moving average price of $2.35 and a two-hundred day moving average price of $2.73. Barinthus Biotherapeutics has a twelve month low of $1.64 and a twelve month high of $5.10. The company has a market cap of $71.42 million, a price-to-earnings ratio of -0.99 and a beta of -0.46.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.24. Equities analysts expect that Barinthus Biotherapeutics will post -2.3 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on BRNS. Barclays dropped their target price on Barinthus Biotherapeutics from $7.00 to $3.00 and set an “overweight” rating for the company in a research report on Thursday. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Barinthus Biotherapeutics in a report on Friday, June 7th. Finally, William Blair reiterated an “outperform” rating on shares of Barinthus Biotherapeutics in a report on Thursday.

Institutional Investors Weigh In On Barinthus Biotherapeutics

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. BlueCrest Capital Management Ltd acquired a new stake in Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 542,673 shares of the company’s stock, valued at approximately $1,292,000. BlueCrest Capital Management Ltd owned about 1.39% of Barinthus Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.